Bank of America (BofA) Securities on Wednesday initiated coverage on Ligand Pharmaceuticals Inc LGND, citing the distinctive ...

Ligand Pharmaceuticals (LGND) stock jumps premarket as BofA starts its coverage with a Buy rating and a $244 target, citing ...

Bank of America has initiated coverage of Ligand Pharmaceuticals Inc (NASDAQ:LGND) with a Buy rating and a $244 price target, citing the company’s royalty-focused business model and diversified ...

Ligand Pharmaceuticals is Tuesday's IBD Stock Of The Day. The biotech stock has blown past several buy points on its way to a new breakout.

In late February 2026, Ligand Pharmaceuticals reported past fourth-quarter 2025 revenue of US$59.67 million and full-year 2025 revenue of US$268.09 million, moving from a prior-year net loss to net ...

Summers Value Partners, an investment management company, released its third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The Summers Value Fund LP returned a net return ...

Fintel reports that on March 11, 2026, B of A Securities initiated coverage of Ligand Pharmaceuticals Incorporated - Equity Right (OTCPK:LGNDZ) with a Buy recommendation. Analyst Price Forecast ...

4 analysts have expressed a variety of opinions on Ligand Pharmaceuticals (NASDAQ:LGND) over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below provides a ...

As of Thursday, February 26, Ligand Pharmaceuticals Incorporated’s LGND share price has dipped by 5.99%, which has investors questioning if this is right time to buy.

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor conferences: Leerink Partners Global Healthcare ...

Good morning, everyone, and welcome to Ligand's Third Quarter 2025 Earnings Call. During the call today, we will review the financial results we released earlier today and provide commentary on our ...